These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 3895852)
21. Leukocyte migration inhibition in vitro in bladder carcinoma. Lavergne JA; Lamm DL; Radwin HM; Harrington JT Cancer Res; 1979 Jun; 39(6 Pt 1):1985-8. PubMed ID: 445398 [TBL] [Abstract][Full Text] [Related]
22. [Carcinoma in situ of the urinary bladder: clinical experience and preliminary study of Thomsen-Friedenreich antigen]. Sasaki K; Maru A; Sakashita S; Koyanagi T Nihon Hinyokika Gakkai Zasshi; 1984 Feb; 75(2):269-77. PubMed ID: 6379252 [No Abstract] [Full Text] [Related]
23. Prognostic significance of circulating cytotoxic lymphocytes against autologous tumors in patients with bladder cancer. Mizutani Y; Okada Y; Terachi T; Yoshida O J Urol; 1996 Mar; 155(3):888-92; discussion 892-4. PubMed ID: 8583600 [TBL] [Abstract][Full Text] [Related]
24. Urinary fibronectin as a predictor of a residual tumour load after transurethral resection of bladder transitional cell carcinoma. Li LY; Yang M; Zhang HB; Su XK; Xu WF; Chen Y; Shen ZJ; Gao X BJU Int; 2008 Aug; 102(5):566-71. PubMed ID: 18410436 [TBL] [Abstract][Full Text] [Related]
25. [Isoantigens ABH in bladder tumors as an indicator of malignant potential. IV. Correlation with Thomsen-Friedenreich antigen and CEA]. Nasu Y; Kumon H; Matsumura Y; Ohmori H Nihon Hinyokika Gakkai Zasshi; 1986 Sep; 77(9):1511-8. PubMed ID: 3807094 [No Abstract] [Full Text] [Related]
26. Multiple cell markers in bladder cancer. Principles and clinical applications. Javadpour N Urol Clin North Am; 1984 Nov; 11(4):609-16. PubMed ID: 6390912 [TBL] [Abstract][Full Text] [Related]
27. [Expression of bcl-2 and p16 in transitional cell carcinoma of urinary bladder]. Leng J; Zhang Y; Yao X; Wen K Zhonghua Wai Ke Za Zhi; 2000 Jan; 38(1):40-3. PubMed ID: 11831985 [TBL] [Abstract][Full Text] [Related]
28. [A study of the T-antigen in ovarian tumor]. Tenjin H Nihon Sanka Fujinka Gakkai Zasshi; 1990 Jan; 42(1):30-6. PubMed ID: 2153744 [TBL] [Abstract][Full Text] [Related]
29. Distribution of CD1a-positive Langerhans cells and lymphocyte subsets in transitional cell carcinoma of the urinary bladder. An immunohistological study on frozen sections. Ioachim-Velogianni E; Stavropoulos NE; Kitsiou E; Stefanaki S; Agnantis NJ J Pathol; 1995 Dec; 177(4):401-6. PubMed ID: 8568595 [TBL] [Abstract][Full Text] [Related]
30. [Prognostic factors for progression of superficial bladder cancer]. Sato N; Sumiya H; Isaka S; Shimazaki J; Matsuzaki O Nihon Hinyokika Gakkai Zasshi; 1992 Aug; 83(8):1263-9. PubMed ID: 1405165 [TBL] [Abstract][Full Text] [Related]
31. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2. Haitel A; Posch B; El-Baz M; Mokhtar AA; Susani M; Ghoneim MA; Marberger M J Urol; 2001 May; 165(5):1481-7. PubMed ID: 11342901 [TBL] [Abstract][Full Text] [Related]
32. Autoantibodies against P53 protein in patients with transitional cell carcinoma of the bladder. Sanchez-Carbayo M; Chulia MT; Niveiro M; Aranda I; Mira A; Soria F Anticancer Res; 1999; 19(4C):3531-7. PubMed ID: 10629648 [TBL] [Abstract][Full Text] [Related]
33. [Tumor bladder antigen (TBA). A new method for the diagnosis and detection of recurrence of bladder cancer]. Escaf Barmadah S; Martín Benito JL; Fernández Gómez JM; San Martín Blanco A; Pérez Gracia FJ; Rodríguez Martínez JJ Arch Esp Urol; 1998 Mar; 51(2):129-36. PubMed ID: 9586309 [TBL] [Abstract][Full Text] [Related]
34. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors. Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289 [TBL] [Abstract][Full Text] [Related]
35. Avidin-biotin technique is more sensitive than lectin assay for detecting the Thomsen-Friedenreich antigen (T-antigen) in transitional cell carcinoma of the bladder. McAlpine RG; Javadpour N; Vafier JA; Worsham GF; O'Connell KJ J Surg Oncol; 1984 Dec; 27(4):255-9. PubMed ID: 6389987 [TBL] [Abstract][Full Text] [Related]
36. [Different expressions of various epitopes of the Thomsen-Friedenreich antigen in breast cancer cells. Immunohistochemical study with monoclonal antibodies against asialoglycophorin A]. Bein G; Poschmann A; Seitz RC; Böcker W Verh Dtsch Ges Pathol; 1985; 69():218-21. PubMed ID: 2420088 [No Abstract] [Full Text] [Related]
37. [The study of Thomsen-Friedenreich antigen and prognosis of the patients with bladder tumor]. Kobayashi H; Obata K; Andou M Nihon Hinyokika Gakkai Zasshi; 1987 Apr; 78(4):674-9. PubMed ID: 3312742 [No Abstract] [Full Text] [Related]
39. Thomsen-Friedenreich-related antigen in non-neoplastic ureter urothelium and transitional cell tumours of the urinary bladder. An immunohistochemical study employing the monoclonal antibody 49H.8. Juhl BR; Hartzen SH; Hainau B Acta Pathol Microbiol Immunol Scand A; 1987 Mar; 95(2):83-91. PubMed ID: 3551496 [TBL] [Abstract][Full Text] [Related]
40. [The p53 positivity in non-tumor mucosa in patients with superficial urinary bladder cancer]. Soukup V; Babjuk M; Dusková J; Pesl M; Szakácsova M; Zámefnik L; Dvorácek J Cas Lek Cesk; 2007; 146(1):63-7. PubMed ID: 17310587 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]